JP5524442B2 - 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬 - Google Patents

呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬 Download PDF

Info

Publication number
JP5524442B2
JP5524442B2 JP2006551761A JP2006551761A JP5524442B2 JP 5524442 B2 JP5524442 B2 JP 5524442B2 JP 2006551761 A JP2006551761 A JP 2006551761A JP 2006551761 A JP2006551761 A JP 2006551761A JP 5524442 B2 JP5524442 B2 JP 5524442B2
Authority
JP
Japan
Prior art keywords
glycopyrrolate
medicament
formoterol
treatment
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006551761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520506A (ja
JP2007520506A5 (enExample
Inventor
ゲーデ，ヨアヒム
マウス，ヨアヒム
ユルゲン クノタ，ペーター
セレニイ，イストバン
Original Assignee
メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト filed Critical メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト
Publication of JP2007520506A publication Critical patent/JP2007520506A/ja
Publication of JP2007520506A5 publication Critical patent/JP2007520506A5/ja
Application granted granted Critical
Publication of JP5524442B2 publication Critical patent/JP5524442B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2006551761A 2004-02-06 2005-01-24 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬 Expired - Fee Related JP5524442B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54195704P 2004-02-06 2004-02-06
US60/541,957 2004-02-06
PCT/EP2005/000649 WO2005074900A2 (en) 2004-02-06 2005-01-24 NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES

Publications (3)

Publication Number Publication Date
JP2007520506A JP2007520506A (ja) 2007-07-26
JP2007520506A5 JP2007520506A5 (enExample) 2008-02-14
JP5524442B2 true JP5524442B2 (ja) 2014-06-18

Family

ID=34837534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006551761A Expired - Fee Related JP5524442B2 (ja) 2004-02-06 2005-01-24 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬

Country Status (19)

Country Link
US (3) US20050175549A1 (enExample)
EP (1) EP1718336B1 (enExample)
JP (1) JP5524442B2 (enExample)
CN (1) CN1905902A (enExample)
AT (1) ATE399027T1 (enExample)
AU (1) AU2005210083B2 (enExample)
CA (1) CA2550841C (enExample)
CY (1) CY1108326T1 (enExample)
DE (1) DE602005007708D1 (enExample)
DK (1) DK1718336T3 (enExample)
ES (1) ES2309705T3 (enExample)
HR (1) HRP20080439T3 (enExample)
NO (1) NO337128B1 (enExample)
NZ (1) NZ548302A (enExample)
PL (1) PL1718336T3 (enExample)
PT (1) PT1718336E (enExample)
RU (1) RU2438660C2 (enExample)
SI (1) SI1718336T1 (enExample)
WO (1) WO2005074900A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
WO2005074918A1 (en) * 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
ES2389231T3 (es) * 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
US20080031828A1 (en) * 2006-08-03 2008-02-07 Boehringer Ingelheim International Gmbh Method for the Treatment of Dyspnea Comprising Combined Administration of Tiotropium Salts and Salts of Salmeterol
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2221048A1 (en) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
EP3106149B1 (en) * 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US20110132355A1 (en) * 2009-06-09 2011-06-09 William Gerhart Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CA2785349C (en) * 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2011076842A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
BR112012015335B1 (pt) * 2009-12-23 2021-05-18 Chiesi Farmaceutici S.P.A. formulação de aerossol para doença pulmonar obstrutiva crõnica
RS53391B2 (sr) * 2009-12-23 2023-09-29 Chiesi Farm Spa Kombinovana terapija copd-a (hroničnih obstruktivnih bolesti pluća)
RU2013142268A (ru) 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
BR112013029507A2 (pt) * 2011-05-17 2019-09-24 Pearl Therapeutics Inc método para tratar uma doença ou um distúrbio
BR112015022784B1 (pt) 2013-03-15 2023-02-14 Pearl Therapeutics, Inc Método de condicionamento de material cristalino micronizado e sistemas de condicionamento
DK3089735T3 (en) * 2013-12-30 2018-09-17 Chiesi Farm Spa STABLE PRESSURE AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION
CN105848642A (zh) * 2013-12-30 2016-08-10 奇斯药制品公司 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物
WO2017077488A1 (en) * 2015-11-04 2017-05-11 Glenmark Pharmaceuticals Limited An inhalable fixed dose powder composition comprising glycopyrronium and formoterol
CA3152578A1 (en) 2019-12-02 2021-06-10 Enrico Zambelli Stainles steel can for pressurised metered dose inhalers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000016A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
EP1369414A1 (de) 1996-11-11 2003-12-10 Christian R. Noe Enantiomerenreine Arylcycloalkyl-Hydroxycarbonsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung als Muskarinrezeptor-Modulatoren
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
RU2221552C2 (ru) * 1998-11-13 2004-01-20 Джаго Рисерч Аг Сухой порошок для ингаляции
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0008485D0 (en) * 2000-04-07 2000-05-24 Glaxo Group Ltd Pharmaceutical compositions
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods

Also Published As

Publication number Publication date
RU2006132036A (ru) 2008-03-20
US7985766B2 (en) 2011-07-26
SI1718336T1 (sl) 2008-10-31
PL1718336T3 (pl) 2008-11-28
EP1718336B1 (en) 2008-06-25
WO2005074900A3 (en) 2006-04-06
AU2005210083A1 (en) 2005-08-18
AU2005210083B2 (en) 2010-03-11
JP2007520506A (ja) 2007-07-26
CN1905902A (zh) 2007-01-31
NO337128B1 (no) 2016-01-25
DK1718336T3 (da) 2008-10-20
CA2550841C (en) 2012-10-02
NO20063882L (no) 2006-10-26
NZ548302A (en) 2010-04-30
PT1718336E (pt) 2008-08-28
CY1108326T1 (el) 2014-02-12
RU2438660C2 (ru) 2012-01-10
ES2309705T3 (es) 2008-12-16
HRP20080439T3 (hr) 2008-10-31
US20070270481A1 (en) 2007-11-22
ATE399027T1 (de) 2008-07-15
WO2005074900A2 (en) 2005-08-18
DE602005007708D1 (de) 2008-08-07
CA2550841A1 (en) 2005-08-18
EP1718336A2 (en) 2006-11-08
US20060252815A1 (en) 2006-11-09
US20050175549A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
JP5524442B2 (ja) 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬
CN1399540A (zh) 包含福莫特罗的气雾剂组合物
SK285884B6 (sk) Kombinovaný prípravok formoterolu a tiotrópiovej soli, jeho použitie a farmaceutická súprava, ktoráho obsahuje
EA008828B1 (ru) Лекарство, содержащее сильнодействующий бета2-агонист длительного действия в комбинации с другими активными ингредиентами
AU2005316687B2 (en) Compositions and methods for pulmonary conditions
WO2009090008A1 (en) Dry powder formulation comprising an anticholinergic drug
CA2688542A1 (en) Methods and compositions for administration of oxybutynin
AU2003292120A1 (en) New synergistic combination comprising roflumilast and formoterol
JP2012506860A (ja) アルホルモテロール及びチオトロピウムの組成物及びその使用方法
AU2003288169B8 (en) Synergistic combination comprising roflumilast and (R,R) -formoterol
CA2815035A1 (en) Carbonate derivatives for the treatment of cough
HK1098355A (en) NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
MXPA06008936A (en) NOVEL COMBINATION OF ANTICHOLINERGIC AND beta MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2006030221A1 (en) Pharmaceutical composition comprising a betaminetic agent and a mucolytic agent
Sacks The use of an isopyrine-phenylbutazone compound in migraine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120106

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140410

R150 Certificate of patent or registration of utility model

Ref document number: 5524442

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees